Our Testing & Evaluation Services

Early Detection. Personalized Support. Empowered Planning.

At Live Well Clinic, we understand that early and accurate evaluation of cognitive health—especially related to Alzheimer’s—is vital for effective planning and care. That’s why we offer a comprehensive testing approach designed to support early detection, informed decisions, and holistic care.

Why This Matters

• Early diagnosis offers critical advantages: It enables timely intervention with emerging treatments, access to clinical trials, and helps patients and families plan for the future with confidence.

• Combines innovation with compassion: We provide the latest non-invasive diagnostic tools in a supportive environment—so you're seen as a person, not just a symptom.

• Tailored, integrative care: Our diagnostics inform personalized pathways—whether that means symptom management, lifestyle counseling, neuro-supportive therapies, or coordination with specialists.

Current therapy does not work because it is like fixing the roof on a house once it has burned down.    Removing the Beta amyloid plaque does not reverse the disease process or prevent cell death.  Removing the plaque is futile, especially after 30 years of disease process that has burned down the house and thy neuron is dead. The pharmaceutical industry is trying to put out the fire after the house has burned down.  Once the damage is done, it makes no sense to remove beta-amyloid plaque from the outside of the neuron when the tau tangles and aggregates have destroyed the inside of the neuron which is now dead or non-functioning.      To prevent and improve Alzheimer’s Disease we need to  address the cause instead of removing the end pathologic product with monoclonal antibodies.   We need to prevent the fire from occurring as well as put it out in the early stages, before the beta-amyloid plaque and tau tangles destroy the house from the inside.     Therefore, the medications that are used to stop the production of beta-amyloid have not been demonstrated to be effective.

There is growing evidence that Alzheimer’s Disease is mediated by tau pathology and not amyloid.   

Risk Factors:

Cardiovascular Disease

Obesity (increase in abdominal fat)

Inflammation in the body:   elevated inflammatory markers, elevated triglycerides, low HDL, elevated apo-B (norma 60-140), elevated HgBA1C

-Family History

Apoe4+

Type 2 Diabetes decreases the availably of glucose in the brain which leads to faster cognitive decline.

Insulin Resistance and decrease in glucose utilization are the main factors in initiation of AD.  AD starts to form 20-30 years before clinical symptoms are present.

Elevated blood sugar and lipids cause microvascular disease which leads to vascular dementia.

Decreased Estrogen Levels after menopause:   Estrogen has significant effects in reducing diabetes, improves insulin levels without the side effects of driving glucose into the cell to be stored as fat as with diabetic medications.   Estrogen improves all lipids and lipoproteins that lead to a decrease in CVD and dementia.

Alzheimer’s Disease that develops later in age is the result of gradual, complex changes that accumulate in the brain over decades.

One of the first signs of Alzheimer’s disease is mild memory impairment.

Dementia is activated by a combination of environmental, lifestyle, and genetic factors.   Risk factors that increase the risk of dementia vary from each individual and depend on genetic influence.

Lifestyle changes and medications can serve as effective treatments of Alzheimer’s Disease.

The best way to address health problems is to treat the root causes.    Hormones decline as we age.  Hormone replacement therapy treats the root cause of many age-related ailments.

One of the most important risk factors for the development of Alzheimer’s disease is being positive for the ApoE4 gene.    ApoE4 is a protein that transports cholesterol and cholesterol-like molecules around the blood stream.   ApoE4 interacts with the cell that can lead to Late onset Alzheimer’s Disease.     Everyone has 2 sets of the ApoE gene, one from your mother and one from your father.     ApoE4 significantly increases risk for late onset AD.    ApoE3 has a 15% overall lifetime risk of developing AD.   If a person has two copies of ApoE4, and does nothing to address the contributing factors, they will have a 91% chance of developing Alzheimer’s disease by the time they are 68 years old.   

Alzheimer’s effects women more so than men.   Studies show that a decrease in estrogen after menopause can be a contributing factor.    Women who have had surgical menopause at a younger age have an increased risk of developing AD.   There is a 83% decreased risk of developing Alzheimer’s Disease in women who begin estrogen therapy within a 10 year window of menopause.